Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review

Table 2

Trials that directly compared liposomal anthracyclines with conventional anthracyclines, either in monotherapy or combination.

Author	Trial phase	Treatment regimen	Patients’ characteristics	PFS	OS	RR	Toxicity
O’Brien et al. [33]	III	PLD (50 mg/m^2/4w); versus; ADR (60 mg/m^2/3w)	Stage IV	6.9 m; versus; 7.8 m	21 m; versus; 22 m	33%; versus; 38%	Cardiac: 4.7 versus 19.6%; CHF: 0% versus 4%
Harris et al.; [34]	III	LD (75 mg/m^2/3w); versus; ADR (75 mg/m^2/3w)	Stage IV; (17% ADR previous)	3.8 m; versus; 4.3 m	16 m; versus; 20 m	26%	Cardiac: 13 versus 29%; CHF: 5.9 versus 15%; Billingham > 2.5: 26 versus 71%
Batist et al.; [35]	III	LD (60 mg/m^2) + CTX (600 mg/m^2); versus; ADR (60 mg/m^2) + CTX (600 mg/m^2)	Stage IV; (10% ADR previous); (30% CRF)	5.1 m; versus; 5.5 m	19 m; versus; 16 m		Cardiac: 6 versus 21% (𝑃<0.05); CRF: 0 versus 3.2%
Chan et al.; [36]	III	LD (75 mg/m^2) + CTX (600 mg/m^2); versus; EPI (75 mg/m^2) + CTX (600 mg/m^2)	Stage IV; (No ADR previous)	7.7 m; versus; 5.6 m	18.3 m; versus; 16 m	46 %; versus; 39 %	Cardiac: 11 versus 10%; No CRF
Sparano et al. [37]	III	Docetaxel (75 mg/m^2); versus; Docetaxel (60 mg/m^2) + PLD (30 mg/m^2)	Stage IV; (100% ADR previous)	7 m; versus; 9.8 m	20.6 m; versus; 20.5 m		Cardiac: 4 versus 5%; PPS: 0 versus 24%

PLD: pegylated liposomal doxorubicin; LD: liposomal doxorubicin; ADR: adriamycin; EPI: epirubicin; CTX: cyclophosphamide; PFS: progression-free survival; OS: overall survival; RR: response rate; PPS: plantar-palmar syndrome; CHF: clinical heart failure; and CRF: cardiac risk factor.